摘要:日前,欧洲药品管理局(EMA)人用医药产品委员会(CHMP)推荐批准瑞士生物技术公司Tesaro旗下PARP抑制剂Zejula用于卵巢癌维持治疗,这也为该公司同阿斯利康及CovisOncology相竞争增添了砝码。
注:因版权方要求,不能公开全文,如需全文,请咨询杂志社
热门期刊服务
川化 测绘 Cell Research Nuclear Science and Techniques Chinese Journal of Cancer Research Neural Regeneration Research Plasma Science and Technology High Technology Letters Tsinghua Science and Technology Journal of Beijing Institute of Technology Journal of Iron and Steel Research Journal of Harbin Institute of Technology